These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 15883662

  • 1. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M, Bultink IE, Dijkmans BA, Lems WF.
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [Abstract] [Full Text] [Related]

  • 2. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
    Omidvar B, Ghorbani A, Shahbazian H, Beladi Mousavi SS, Shariat Nabavi SJ, Alasti M.
    Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
    [Abstract] [Full Text] [Related]

  • 3. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA, Peacock M.
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [Abstract] [Full Text] [Related]

  • 4. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC, Juttmann JR, Wolffenbuttel BH.
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 6. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.
    Eekman DA, Vis M, Bultink IE, Derikx HJ, Dijkmans BA, Lems WF.
    BMC Musculoskelet Disord; 2009 Jul 15; 10():86. PubMed ID: 19604377
    [Abstract] [Full Text] [Related]

  • 7. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun 15; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH, Adams-Huet B, Poindexter JR, Maalouf NM.
    Osteoporos Int; 2016 May 15; 27(5):1701-8. PubMed ID: 26642963
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.
    Intern Med J; 2011 Feb 15; 41(2):186-90. PubMed ID: 20214696
    [Abstract] [Full Text] [Related]

  • 17. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan 15; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 18. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
    Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I.
    Osteoporos Int; 2000 Jan 15; 11(2):171-6. PubMed ID: 10793877
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.